2026/2027 | VERSION 1 | EVIDENCE-BASED SOLUTIONS |
GRADED A+ Q&A | PASS GUARANTEED - A+ GRADED
The Menopause Society Certified Practitioner (MSCP)
Comprehensive Practice Examination 2026/2027
Version 1 — Evidence-Based Practice Questions with Answers and
Rationales
Course Code: MSCP
Course Name: Menopause and Midlife Women's Health
Institution: The Menopause Society
Examination Type: Comprehensive Practice Examination
Version: 1
Question Count: 100
Format: Multiple Choice and Short Answer
Purpose: Examination preparation and knowledge assessment
Status: Original practice material
IMPORTANT NOTICE
This document contains original practice questions created for educational
preparation
The current MSCP examination is administered by The Menopause Society. The
Society states that there is no official study guide and recommends using its
professional educational resources together with other reputable sources. The
examination competency framework covers menopause physiology, symptoms and
concerns, health conditions, and management.
Clinical recommendations can change. Candidates should verify management
decisions against current professional guidelines, prescribing information, and
local standards before clinical application.
,TABLE OF CONTENTS
1. Menopause Physiology and Reproductive Aging — Questions 1–10
2. Vasomotor, Sleep, Mood, Cognitive, and Other Symptoms — Questions 11–20
3. Genitourinary Syndrome, Sexual Health, and Pelvic Floor — Questions 21–30
4. Hormone Therapy and Nonhormone Therapy — Questions 31–40
5. Abnormal Uterine Bleeding, Breast Health, and Gynecologic Issues — Questions 41–50
6. Bone Health and Osteoporosis — Questions 51–60
7. Cardiovascular and Metabolic Health — Questions 61–70
8. Cancer, Thrombosis, and Special Populations — Questions 71–80
9. Lifestyle, Weight, Skin, Hair, and Musculoskeletal Health — Questions 81–90
10. Clinical Integration and Case-Based Management — Questions 91–100
SECTION 1
MENOPAUSE PHYSIOLOGY AND REPRODUCTIVE AGING
Question 1 — Multiple Choice
Which definition most accurately describes menopause?
A. The first year in which menstrual cycles become irregular
B. Permanent cessation of menstruation caused by loss of ovarian follicular activity, diagnosed
retrospectively after 12 months of amenorrhea
C. Any menstrual period occurring after age 45
D. A decline in estrogen beginning approximately 10 years before the final menstrual period
Correct answer: B
Rationale: Natural menopause is diagnosed retrospectively after 12 consecutive months without
menstruation when no other cause explains the amenorrhea. It reflects the end of ovarian
follicular activity. The menopause transition begins earlier and is characterized by changing
cycle regularity and ovarian hormonal dynamics.
Question 2 — Short Answer
,What is the final menstrual period (FMP), and why is it clinically important?
Correct answer: The FMP is the last menstrual period in a person's reproductive life, but it can
only be confirmed retrospectively after 12 consecutive months of amenorrhea without another
explanation.
Rationale: The FMP is a biological milestone used to define the transition from reproductive life
into postmenopause. Because menstruation can be irregular during perimenopause, clinicians
cannot identify the final period prospectively with certainty.
Question 3 — Multiple Choice
Which hormonal pattern is most characteristic of the menopause transition?
A. Persistently elevated estradiol and suppressed FSH
B. Progressive ovarian follicular depletion accompanied by increasingly variable ovarian
hormone production
C. Complete cessation of ovarian estrogen production immediately after the first irregular cycle
D. Persistently low FSH with progressively increasing progesterone
Correct answer: B
Rationale: The menopause transition is characterized by declining follicular reserve and
increasingly variable ovarian function. Estradiol may fluctuate substantially, while FSH
generally rises as ovarian feedback becomes less effective. Hormonal variability helps explain
why a single hormone measurement often has limited diagnostic value in typical perimenopause.
Question 4 — Multiple Choice
Which statement about STRAW+10 is correct?
A. It classifies menopause exclusively according to serum estradiol levels
B. It provides a standardized framework for describing reproductive aging stages
C. It applies only to women after menopause
D. It eliminates the need to consider menstrual-cycle changes
Correct answer: B
Rationale: STRAW+10 provides a standardized staging system for reproductive aging.
Menstrual-cycle characteristics are central to the staging system, with hormonal biomarkers
providing additional information in selected circumstances.
, Question 5 — Short Answer
Why is routine measurement of serum FSH usually unnecessary for diagnosing menopause in a
healthy person aged 45 years or older with typical menopausal symptoms and menstrual
changes?
Correct answer: The clinical history and menstrual pattern are generally sufficient, while FSH
fluctuates substantially during the menopause transition and a single measurement may not
accurately represent ovarian function.
Rationale: Hormonal variability can produce misleading results during perimenopause. Testing
is more useful when the diagnosis is uncertain, particularly in younger patients or when
alternative causes of amenorrhea need consideration.
Question 6 — Multiple Choice
A 42-year-old has had amenorrhea for 8 months and reports hot flashes. Which diagnosis
requires particular consideration because of her age?
A. Normal postmenopause without further evaluation
B. Primary ovarian insufficiency
C. Osteoarthritis
D. Normal aging alone
Correct answer: B
Rationale: Menopause occurring before age 45 is considered early menopause, while ovarian
insufficiency occurring before age 40 is classified as primary ovarian insufficiency (POI). A
patient younger than 45 with amenorrhea and estrogen-deficiency symptoms warrants
assessment for causes of early ovarian dysfunction.
Question 7 — Multiple Choice
Which consequence is particularly important in untreated primary ovarian insufficiency?
A. Reduced lifetime exposure to estrogen-related bone and cardiovascular protection
B. Permanent protection against osteoporosis
C. Increased ovarian reserve
D. Guaranteed infertility with no possibility of intermittent ovarian activity
Correct answer: A